Status
Conditions
Treatments
About
The present study is a randomized, placebo-controlled, parallel-group, double-blind clinical study. Seventy-eight individuals will be screened, and considering a screening failure rate of 20%, approximately 64 participants will be randomized in a ratio of 1:1 to receive either BioPB-01 or Placebo
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
64 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Dr. Sonal Raote, BAMS; Dr. Shalini Srivastava, MBBS, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal